Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma

بواسطة Moore, N.F, Azarova, A.M, Bhatnagar, N, Ross, K.N, Drake, L.E, Frumm, S, Liu, Q.S, Christie, A.L, Sanda, T, Chesler, L, Kung, A.L, Gray, N.S, Stegmaier, K, George, R.E
منشور في 2020

Characterization of notch1 antibodies that inhibit signaling of both normal and mutated notch1 receptors

بواسطة Aste-Am閦aga M., Zhang N., Lineberger J.E., Arnold B.A., Toner T.J., Gu M., Huang L., Vitelli S., Vo K.T., Haytko P., Zhao J.Z., Baleydier F., L'Heureux S., Wang H., Gordon W.R., Thoryk E., Andrawes M.B., Tiyanont K., Stegmaier K., Roti G., Ross K.N., Franlin L.L., Wang H., Wang F., Chastain M., Bett A.J., Audoly L.P., Aster J.C., Blacklow S.C., Huber H.E.
منشور في 2019